NCT04685603 is a Phase 1 clinical trial of AV-COVID-19 in COVID-19, sponsored by Indonesia-MoH.

Who is sponsoring NCT04685603?

NCT04685603 is sponsored by Indonesia-MoH.

What drugs are being tested in NCT04685603?

Interventions in NCT04685603: AV-COVID-19.

Is NCT04685603 still recruiting?

NCT04685603 is currently status unknown. Last updated 29 December 2020.

Last reviewed 2020-12-29 · How we verify

NCT04685603

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dendritic Cell Vaccine to Prevent COVID-19

Status unknown Phase 1 Last updated 29 December 2020

What this trial tests

Phase 1 trial testing AV-COVID-19 in COVID-19 in 27 participants. Status unknown.

Timeline

7 December 2020

Primary endpoint
31 January 2021

31 January 2022

Quick facts

Lead sponsor	Indonesia-MoH
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	27
Start date	7 December 2020
Primary completion	31 January 2021
Estimated completion	31 January 2022
Sites	1 location across Indonesia

Drugs / interventions tested

AV-COVID-19 — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Indonesia-MoH

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and safety of COVID-19 vaccines.
Graña C, Ghosn L, Evrenoglou T, Jarde A, et al · · 2022 · cited 227× · PMID 36473651 · DOI 10.1002/14651858.cd015477
COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials.
Yan ZP, Yang M, Lai CL. · · 2021 · cited 89× · PMID 33923054 · DOI 10.3390/ph14050406
Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities.
Alahdal M, Elkord E. · · 2022 · cited 48× · PMID 36356848 · DOI 10.1016/j.clim.2022.109177
Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena.
Chavda VP, Bezbaruah R, Athalye M, Parikh PK, et al · · 2022 · cited 40× · PMID 35458489 · DOI 10.3390/v14040759
Vitamin C enhances NF-κB-driven epigenomic reprogramming and boosts the immunogenic properties of dendritic cells.
Morante-Palacios O, Godoy-Tena G, Calafell-Segura J, Ciudad L, et al · · 2022 · cited 38× · PMID 36305821 · DOI 10.1093/nar/gkac941
COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches.
Zavvar M, Yahyapoor A, Baghdadi H, Zargaran S, et al · · 2022 · cited 13× · PMID 35248946 · DOI 10.1016/j.intimp.2022.108655
An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19.
Monzavi SM, Naderi M, Ahmadbeigi N, Kajbafzadeh AM, et al · · 2021 · cited 9× · PMID 34217004 · DOI 10.1016/j.cellimm.2021.104398
Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach.
Das A, Roy S, Swarnakar S, Chatterjee N. · · 2021 · cited 6× · PMID 34303849 · DOI 10.1016/j.clim.2021.108804

Verify or expand the search:

Other trials of AV-COVID-19

Trials testing the same drug.

NCT05007496 — Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19 · Phase 2 · completed
NCT04690387 — Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection · Phase 1 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04685603 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Indonesia-MoH
Last refreshed: 29 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04685603.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing